- Home
- LENZ vs AVDL Comparison
LENZ vs AVDL Comparison
Compare LENZ & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- AVDL
- Stock Information
- Founded
- LENZ 2019
- AVDL 2015
- Country
- LENZ United States
- AVDL Ireland
- Employees
- LENZ N/A
- AVDL N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- LENZ Health Care
- AVDL Health Care
- Exchange
- LENZ Nasdaq
- AVDL Nasdaq
- Market Cap
- LENZ 886.2M
- AVDL 993.5M
- IPO Year
- LENZ 2021
- AVDL 1996
- Fundamental
- Price
- LENZ $32.63
- AVDL $10.31
- Analyst Decision
- LENZ Strong Buy
- AVDL Strong Buy
- Analyst Count
- LENZ 6
- AVDL 6
- Target Price
- LENZ $35.40
- AVDL $24.00
- AVG Volume (30 Days)
- LENZ 154.8K
- AVDL 1.3M
- Earning Date
- LENZ 11-06-2024
- AVDL 11-12-2024
- Dividend Yield
- LENZ N/A
- AVDL N/A
- EPS Growth
- LENZ N/A
- AVDL N/A
- EPS
- LENZ N/A
- AVDL N/A
- Revenue
- LENZ N/A
- AVDL $138,160,000.00
- Revenue This Year
- LENZ N/A
- AVDL $523.86
- Revenue Next Year
- LENZ N/A
- AVDL $70.46
- P/E Ratio
- LENZ N/A
- AVDL N/A
- Revenue Growth
- LENZ N/A
- AVDL 1523.50
- 52 Week Low
- LENZ $2.33
- AVDL $9.41
- 52 Week High
- LENZ $38.93
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- LENZ 50.06
- AVDL 41.51
- Support Level
- LENZ $28.90
- AVDL $10.35
- Resistance Level
- LENZ $33.30
- AVDL $11.15
- Average True Range (ATR)
- LENZ 2.54
- AVDL 0.59
- MACD
- LENZ -0.62
- AVDL 0.10
- Stochastic Oscillator
- LENZ 42.03
- AVDL 44.34
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.